SEC Form 4 · accession 0000907654-26-000096
Oruka Therapeutics, Inc. · ORKA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Lawrence Otto Klein
Officer — Chief Executive Officer · Director
Period of report
Sep 15, 2026
Accepted (ET)
Sep 15, 2026 · 7:15 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0000907654
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Sep 15, 2026 | S | 2,452 | $95.71 | D | 923,128 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The reported sales were effected pursuant to Oruka Therapeutics, Inc.'s automatic, non-discretionary, sell-to-cover procedure to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units.